Trial Profile
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Abscess; Aspergillosis; Blastomycosis; Candidaemia; Coccidioidomycosis; Endocarditis; Histoplasmosis; Invasive candidiasis; Mediastinitis; Mucocutaneous candidiasis; Mycoses; Oesophagitis; Oropharyngeal candidiasis; Osteomyelitis; Vulvovaginal candidiasis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FURI
- Sponsors SCYNEXIS
- 27 Oct 2023 Status changed from active, no longer recruiting to completed.
- 27 Sep 2023 This trial has been completed in Austria (Date of the global end of the trial: 17-Aug-2023), according to the European Clinical Trials Database record.
- 12 Sep 2023 Planned number of patients changed from 200 to 220.